Daptomycin intravenous - Xellia Pharmaceuticals

Drug Profile

Daptomycin intravenous - Xellia Pharmaceuticals

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xellia Pharmaceuticals
  • Class Antibacterials; Cyclic peptides; Lipopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Bacteraemia; Skin and soft tissue infections

Most Recent Events

  • 20 Oct 2017 Registered for Bacteraemia in USA (IV)
  • 20 Oct 2017 Registered for Skin and soft tissue infections in USA (IV)
  • 01 Aug 2017 Registered for Bacteraemia in United Kingdom, Italy, Spain, Germany, Germany, France, Ireland and Austria (IV) before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top